<DOC>
	<DOCNO>NCT00431613</DOCNO>
	<brief_summary>The combination chemotherapy radiotherapy remain standard therapy patient stage III NSCLC . A recent phase II study present encouraging data regard administration docetaxel consolidation treatment definitive concurrent chemo-radiotherapy .</brief_summary>
	<brief_title>Study Docetaxel/Gemcitabine Followed Chemo-radiotherapy ( Chemo-RT ) , With Without Consolidation Chemotherapy , IIIA/IIIB Non Small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description>To evaluate whether administration consolidation therapy docetaxel/carboplatin induction chemotherapy follow concurrent chemoradiotherapy , offer advantage regard time tumor progression</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>histologically cytologically confirm , unresectable locally advanced ( stage IIIA/IIIB ) NSCLC previous therapy NSCLC allow age &gt; 18 year bidimensionally measurable disease performance status ( WHO ) 02 absence pleural effusion adequate liver ( serum bilirubin &lt; 1.5 time upper normal limit ( UNL ) ; AST ALT &lt; 2.5 time UNL absence demonstrable liver metastasis , &lt; 5 time UNL presence liver metastasis ) ; adequate renal function ( serum creatinine &lt; 1.5 time UNL ) ; bone marrow ( neutrophils ≥ 1.5x 109 /L , platelet ≥ 100x 109 /L ) function life expectancy 3 month write informed consent active infection history significant cardiac disease ( unstable angina , congestive heart failure , myocardial infarction within previous 6 month , ventricular arrhythmia ) malnutrition ( loss ≥ 20 % original body weight ) performance status : 34 sensor motor neuropathy &gt; grade I second primary malignancy , except nonmelanoma skin cancer psychiatric illness social situation would preclude study compliance pregnant lactating woman</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>NSCLC</keyword>
	<keyword>Induction chemotherapy</keyword>
	<keyword>Concurrent chemoradiotherapy</keyword>
	<keyword>Consolidation therapy</keyword>
	<keyword>Docetaxel</keyword>
	<keyword>Gemcitabine</keyword>
	<keyword>Carboplatin</keyword>
</DOC>